Business
Why the Immutep (ASX:IMM) share price will be in focus today
Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents.
Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.
New patent added
The Immutep share price could be on the move today following the company’s latest update released after yesterday’s market close
According to its…
-
Noosa News22 hours agoExperts share tiny home warning as interest from young people soars
-
Noosa News21 hours agoExpert’s warning as tourists stunned by hundreds of sharks spotted close to shore at Moreton Island, Queensland
-
General18 hours agoConvicted mushroom murderer Erin Patterson outlines her reasons to appeal
-
General7 hours agoSussan Ley’s net zero problem won’t only impact the Coalition